Calyx Therapeutics is a pharmaceutical company focusing on oral therapies for diabetes and inflammatory diseases. Calyx utilizes natural plant extracts with demonstrated clinical activity in humans as the source of its discovery efforts. The company isolates the biologically active molecule, determines its chemical structure, and aims to develop small molecule analogs. This process aims to reduce the time and investment required to take lead molecules into preclinical and clinical testing.

Joyant Pharmaceuticals is focused on the development of small molecule therapeutics for cancer and inflammation. Joyant is developing several programs based upon their understanding of the molecular events that control growth, replication and apoptosis.

Avidimer Therapeutics is engaged in the discovery and development of therapeutics for inflammatory diseases

Procyon Pharmecuticals, Inc. is an veterinary pharmecutical research and development company with a robust, theraputically diverse pipeline of products being developed to meet the needs of veterinarians and pet owners.

Marval Biosciences is an early stage company, developing contrast agents for use in X-ray and Computed Tomography (CT) Imaging. Marval's lead candidate, NCTX, targets cardiovascular imaging.

Gamida Cell offers treatments for cancer through cell therapy. It uses its proprietary nicotinamide (NAM) technology to enhance and expand cells, creating allogeneic cell therapy products aimed at treating hematologic malignancies. Its activities include the research and development of cell therapies, with an FDA approval for its stem cell transplant therapy and ongoing clinical studies for its NK cell therapy candidate GDA-201. It was founded in 1998 and is based in Naples, Florida.